Pfizer & Hisun to Establish JV for Branded Generics

The two companies aim to strengthen the ability to reach more patients with high-quality and low-cost medicines in the branded generics arena.

Pfizer Inc. and Zhejiang Hisun Pharmaceuticals, a leading pharmaceutical company in China, jointly announced the signing of a memorandum of understanding on their intention to establish a joint venture. The two companies aim to strengthen the ability to reach more patients with high-quality and low-cost medicines in the branded generics arena.

Under the MOU, the two companies will explore a potential business collaboration focused on manufacturing cooperation to deliver high-quality medicines, broader commercialization of medicines through a local and global sales and marketing infrastructure and research and development of off-patent medicines. Both parties could contribute select existing products and other relevant assets and capabilities to provide a solid platform for this potential joint venture.